Jounce Therapeutics Inc $ 7.27 0.58 (8.67%)
Volume:
272,210
Avg Vol (1m):
358,532
Market Cap $:
289.72 Mil
Enterprise Value $:
203.13 Mil
P/E (TTM):
0.00
P/B:
2.35
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 5.91 | ||
| Debt-to-Equity | 0.17 | ||
| Debt-to-EBITDA | -0.18 | ||
| Piotroski F-Score | 2 | ||
| Beneish M-Score | -4.43 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -87.13 | ||
| Net Margin % | -85.38 | ||
| ROE % | -67.91 | ||
| ROA % | -56.29 | ||
| ROC (Joel Greenblatt) % | -389.28 | ||
| 3-Year Revenue Growth Rate | 51.8 |
JNCE
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 2.35 | ||
| PS Ratio | 1.68 | ||
| EV-to-EBIT | -1.94 | ||
| EV-to-EBITDA | -2.02 | ||
| Current Ratio | 6.6 | ||
| Quick Ratio | 6.6 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.8 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 2.36 | ||
| Earnings Yield (Greenblatt) % | -51.22 |